Sec Form 4 Filing - HALE DAVID F @ Dermata Therapeutics, Inc. - 2021-08-17

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person HALE DAVID F 2. Issuer Name and Ticker or Trading Symbol Dermata Therapeutics, Inc. [ DRMA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 3525 DEL MAR HEIGHTS RD., #332 3. Date of Earliest Transaction (MM/DD/YY) 08/17/2021 (Street) SAN DIEGO, CA92130 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/17/2021 C 44,777 A 299,411 I By Hale BioVentures LLC ( 7 ) Common Stock 08/17/2021 C 12,195 A 311,606 I By Hale BioVentures LLC ( 7 ) Common Stock 08/17/2021 C 20,000 A 331,606 I By Hale BioVentures LLC ( 7 ) Common Stock 08/17/2021 C 174,216 A 505,822 I By Hale BioVentures LLC ( 7 ) Common Stock 08/17/2021 C 27,103 A 532,925 I By Hale BioVentures LLC ( 7 ) Common Stock 08/17/2021 P 35,714 A 35,714 I By Hale Family Trust ( 7 ) Common Stock 3,658 D Common Stock 12,195 I By Hale Trading Company LP ( 7 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series 1d Preferred Stock ( 1 ) 08/17/2021 C 302,112 ( 1 ) ( 1 ) Common Stock 44,777 $ 0 0 I By Hale BioVentures LLC ( 7 ) Series 1a Preferred Stock ( 2 ) 08/17/2021 C 250,000 ( 2 ) ( 2 ) Common Stock 12,195 $ 0 0 I By Hale BioVentures LLC ( 7 ) Series 1b Preferred Stock ( 3 ) 08/17/2021 C 410,000 ( 3 ) ( 3 ) Common Stock 20,000 $ 0 0 I By Hale BioVentures LLC ( 7 ) Series 1c Preferred Stock ( 4 ) 08/17/2021 C 3,571,428 ( 4 ) ( 4 ) Common Stock 174,216 $ 0 0 I By Hale BioVentures LLC ( 7 ) Series 1 Preferred Stock ( 5 ) 08/17/2021 C 555,622 ( 5 ) ( 5 ) Common Stock 27,103 $ 0 0 I By Hale BioVentures LLC ( 7 ) Series 1a Warrants ( 6 ) 08/17/2021 C 62,500 11/15/2016 03/14/2026 Common Stock 3,048 $ 0 0 I By Hale BioVentures LLC ( 7 ) Warrant to Purchase Common Stock $ 20.5 08/17/2021 C 3,048 11/15/2016 03/14/2026 Common Stock 3,048 $ 0 3,048 I By Hale BioVentures LLC ( 7 ) Warrant to Purchase Common Stock $ 7 08/17/2021 P 35,714 08/17/2021 08/17/2026 Common Stock 35,714 ( 8 ) 35,714 I By Hale Family Trust ( 7 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other HALE DAVID F 3525 DEL MAR HEIGHTS RD., #332 SAN DIEGO, CA92130 X X Signatures /s/ Gerald T. Proehl, Attorney-in-Fact 08/17/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. ( 2 )The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. ( 3 )The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. ( 4 )The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. ( 5 )The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. ( 6 )The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO. ( 7 )Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. ( 8 )Reporting Person purchased 35,714 Units in the IPO at $7.00 per Unit. Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.